专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09757462B2 Combined pharmaceutical preparation 有权
公开(公告)号：US09757462B2
公开(公告)日：2017-09-12
申请号：US13885811
申请日：2011-10-20
申请人： Junji Kato , Rishu Takimoto
发明人： Junji Kato , Rishu Takimoto
IPC分类号： A61K47/26 , A61K47/48
CPC分类号： A61K47/26 , A61K47/549 , A61K47/61 , A61K47/6911
摘要： The invention relates to a combined pharmaceutical composition or pharmaceutical preparation, comprising a first component containing a first ligand for a polyspecific lectin in a reticuloendothelial cell and a second component containing a carrier, a labeling agent, or a medicament for treating a disease associated with a target cell, each of which is targeted by a second ligand for a polyspecific lectin in a reticuloendothelial cell different from the first ligand, and also relates to a method for labeling a target cell and a method for treating a disease associated with a target cell, each using the same.

2. 发明授权

US08652526B2 Drug carrier and drug carrier kit for inhibiting fibrosis 有权
标题翻译：用于抑制纤维化的药物载体和药物载体试剂盒
公开(公告)号：US08652526B2
公开(公告)日：2014-02-18
申请号：US13439330
申请日：2012-04-04
申请人： Yoshiro Niitsu , Junji Kato , Yasushi Sato
发明人： Yoshiro Niitsu , Junji Kato , Yasushi Sato
IPC分类号： A61K9/127 , A61K9/14 , A61K31/07 , C12N15/11 , A61K38/18
CPC分类号： A61K31/07 , A61K9/0019 , A61K9/127 , A61K9/14 , A61K31/7088 , A61K38/1833 , A61K38/1841 , A61K38/1858 , A61K45/06 , A61K47/6911 , Y10S514/893 , Y10T428/2982 , A61K2300/00
摘要： An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.
摘要翻译：含有类视黄醇衍生物和/或维生素A类似物作为成分的星形胶质细胞特异性药物载体; 一种使用该药物的药物递送方法; 含有该药物的药物; 以及使用该药物的治疗方法。通过将药物载体与维生素A或维生素A类似物的类视黄醇衍生物结合或将其包封在药物载体中，用于治疗用途的药物可以特异性递送至星形胶质细胞。结果，可以有效地有效地抑制或预防星形胶质细胞相关疾病，同时尽量减少副作用。作为抑制星形胶质细胞活性或生长的药物，例如可以将作为胶原特异性分子伴侣的HSP47的siRNA包封在药物载体中。因此，可以同时抑制I型至IV型胶原的分泌，从而可以有效地抑制纤维化。

3. 发明申请

US20120259492A1 VEHICLE 有权
标题翻译：车辆
公开(公告)号：US20120259492A1
公开(公告)日：2012-10-11
申请号：US13439848
申请日：2012-04-05
申请人： Akihiro YAMAMOTO , Junji Kato , Yuichi Nakamura , Hiroshi Murakami
发明人： Akihiro YAMAMOTO , Junji Kato , Yuichi Nakamura , Hiroshi Murakami
IPC分类号： B60L15/00
CPC分类号： B60K6/52 , B60K7/0007 , B60K17/02 , B60K17/046 , B60K17/356 , B60K2007/0046 , B60K2007/0061 , B60K2007/0092 , Y02T10/6265 , Y10S903/903
摘要： A vehicle includes a first drive device and a second drive device. The first drive device includes a motor, a motor control device, a connection-disconnection device, and a connection-disconnection device controller. When the vehicle is driven in a state where a driving force of the first drive device is substantially zero, or the vehicle is driven only by a driving force of the second drive device, the connection-disconnection device controller couples the connection-disconnection device to establish a connected state of the connection-disconnection device. The motor control device is configured to perform loss reduction control on the motor to reduce at least one of a loss of the motor and a loss in a power transmission path in power transmitted to the first driving wheel, by establishing the connected state of the connection-disconnection device.
摘要翻译：车辆包括第一驱动装置和第二驱动装置。第一驱动装置包括电动机，电动机控制装置，连接断开装置和连接断开装置控制器。当车辆在第一驱动装置的驱动力基本上为零的状态下驱动时，或车辆仅由第二驱动装置的驱动力驱动时，连接断开装置控制器将连接断开装置连接到建立连接断开装置的连接状态。电动机控制装置被配置为对电动机执行减少损失控制，以通过建立连接的连接状态来减少电动机的损失和传递到第一驱动轮的动力的动力传递路径的损失中的至少一个 - 连接设备。

4. 发明申请

US20080193512A1 Drug Carrier and Drug Carrier Kit for Inhibiting Fibrosis 有权
标题翻译：用于抑制纤维化的药物载体和药物载体试剂盒
公开(公告)号：US20080193512A1
公开(公告)日：2008-08-14
申请号：US11793736
申请日：2005-12-22
申请人： Yoshiro Niitsu , Junji Kato , Yasushi Sato
发明人： Yoshiro Niitsu , Junji Kato , Yasushi Sato
IPC分类号： A61K9/127 , A61K31/07 , A61P35/00
CPC分类号： A61K31/07 , A61K9/0019 , A61K9/127 , A61K9/14 , A61K31/7088 , A61K38/1833 , A61K38/1841 , A61K38/1858 , A61K45/06 , A61K47/6911 , Y10S514/893 , Y10T428/2982 , A61K2300/00
摘要： An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.
摘要翻译：含有类视黄醇衍生物和/或维生素A类似物作为成分的星形胶质细胞特异性药物载体; 一种使用该药物的药物递送方法; 含有该药物的药物; 以及使用该药物的治疗方法。通过将药物载体与维生素A或维生素A类似物的类视黄醇衍生物结合或将其包封在药物载体中，用于治疗用途的药物可以特异性递送至星形胶质细胞。结果，可以有效地有效地抑制或预防星形胶质细胞相关疾病，同时尽量减少副作用。作为抑制星形胶质细胞活性或生长的药物，例如可以将作为胶原特异性分子伴侣的HSP47的siRNA包封在药物载体中。因此，可以同时抑制I型至IV型胶原的分泌，从而可以有效地抑制纤维化。

5. 发明申请

US20070192599A1 Authentication method and authentication system 审中-公开
标题翻译：认证方式和认证系统
公开(公告)号：US20070192599A1
公开(公告)日：2007-08-16
申请号：US11338669
申请日：2006-01-25
申请人： Junji Kato , Hirokazu Tsuruta
发明人： Junji Kato , Hirokazu Tsuruta
IPC分类号： H04L9/00
CPC分类号： H04L9/3273 , H04L9/0844 , H04L9/16 , H04L2209/60 , H04L2209/805
摘要： After a selection key bundle is determined by a selection key bundle determining process, the following first authentication key authenticating process is executed. An authentication processing part selects a selection encryption key from selection key bundle following a predetermined association based on a received random-number data. On the other hand, another authentication processing part selects an encryption key from the selection key bundle as a selection encryption key, following the association based on the received random-number data, encrypts the random-number data using the selection encryption key so as to acquire encrypted random-number data and transmits to the former authentication processing part. The former authentication processing part decrypts the encrypted random-number data using the selection encryption key so as to acquire decrypted random-number data and then determines whether that authentication is acceptable based on a comparison between the transmission time original random-number data and decrypted random-number data.
摘要翻译：在通过选择密钥束确定处理确定了选择密钥束之后，执行以下第一认证密钥认证处理。认证处理部基于接收到的随机数数据，在预定关联之后从选择密钥束中选择选择加密密钥。另一方面，另一认证处理部从选择密钥包中选择加密密钥作为选择加密密钥，根据接收的随机数数据进行关联，然后使用选择加密密钥加密随机数数据，从而获取加密的随机数数据并将其发送到前一认证处理部分。前一认证处理部分使用选择加密密钥对加密的随机数数据进行解密，以便获取解密的随机数数据，然后基于传输时间原始随机数数据和解密随机数之间的比较来确定该认证是否可接受数字数据。

6. 发明授权

US07245493B2 Cooler for cooling electric part 有权
标题翻译：冷却器用于冷却电气部件
公开(公告)号：US07245493B2
公开(公告)日：2007-07-17
申请号：US10902803
申请日：2004-08-02
申请人： Mitsuharu Inagaki , Junji Kato , Masahiro Shimoya , Jiro Ebihara , Shinya Noro , Tomoaki Nakano
发明人： Mitsuharu Inagaki , Junji Kato , Masahiro Shimoya , Jiro Ebihara , Shinya Noro , Tomoaki Nakano
IPC分类号： G06F1/20
CPC分类号： H01L25/117 , F28D2021/0029 , H01L23/4334 , H01L23/473 , H01L24/33 , H01L24/48 , H01L25/072 , H01L2224/32245 , H01L2224/48091 , H01L2224/48247 , H01L2224/48472 , H01L2224/73215 , H01L2224/73265 , H01L2924/00014 , H01L2924/01006 , H01L2924/01013 , H01L2924/01033 , H01L2924/1305 , H01L2924/13055 , H01L2924/1306 , H01L2924/181 , H01L2924/1815 , H01L2924/00 , H01L2924/00012 , H01L2224/45099 , H01L2224/45015 , H01L2924/207
摘要： A cooler cools a plurality of electric parts from both sides thereof. The cooler includes a plurality of cooling units including a pair of cooling tubes for flowing coolant therethrough. A pair of cooling tubes having a flat shape is disposed to sandwich the electric part so that both sides of the electric part are cooled by a pair of cooling tubes. The cooling units are disposed to align in a stacking direction. A clearance is disposed between the neighboring cooling units in the stacking direction.
摘要翻译：冷却器从其两侧冷却多个电气部件。冷却器包括多个冷却单元，其包括用于使冷却剂从其中流动的一对冷却管。设置一对具有扁平形状的冷却管，以夹住电气部件，使得电气部件的两侧被一对冷却管冷却。冷却单元设置成沿堆叠方向对齐。在相邻的冷却单元之间沿堆叠方向设置间隙。

7. 发明申请

US20070062671A1 Heat exchanger and production method for the heat exchanger 审中-公开
标题翻译：热交换器的换热器和生产方法
公开(公告)号：US20070062671A1
公开(公告)日：2007-03-22
申请号：US11522787
申请日：2006-09-18
申请人： Naoki Sugimoto , Ryouichi Sanada , Junji Kato
发明人： Naoki Sugimoto , Ryouichi Sanada , Junji Kato
IPC分类号： F28F9/00
CPC分类号： F28F9/002 , F28D1/0452
摘要： A bracket portion and a caulking pawl portion are provided on a tank cap closing an end portion of a first refrigerant header tank of an evaporator. Brazing is carried out in a state where the pawl portion is caulked and provisionally fixed to side plates by the pawl portion. As the evaporator and a radiator for electric components are coupled through the bracket portion, the coupling distance can be reduced and a suitable fastening strength between the evaporator and the radiator for electric components can be secured.
摘要翻译：托架部分和铆接爪部分设置在封闭蒸发器的第一制冷剂集水箱的端部的罐盖上。在爪部被铆接并通过棘爪部临时固定在侧板上的状态下进行钎焊。由于蒸发器和用于电气部件的散热器通过支架部分联接，所以可以减小联接距离，并且可以确保用于电气部件的蒸发器和散热器之间的合适的紧固强度。

8. 发明申请

US20050041774A1 Particulate matter analyzer, collecting filter and system for analyzing and collecting samples from fluids 有权
标题翻译：颗粒物质分析仪，收集过滤器和用于分析和收集流体样品的系统
公开(公告)号：US20050041774A1
公开(公告)日：2005-02-24
申请号：US10824881
申请日：2004-04-15
申请人： Katsumi Saitoh , Junji Kato , Masahiko Fujiwara , Masayoshi Shinohara
发明人： Katsumi Saitoh , Junji Kato , Masahiko Fujiwara , Masayoshi Shinohara
IPC分类号： B01D46/10 , G01N1/22 , G01N15/06 , G01N23/06
CPC分类号： B01D46/0002 , B01D46/0006 , B01D46/10 , G01N1/2202 , G01N1/2205 , G01N15/0625 , Y10S55/03
摘要： A system, including a particulate matter analyzer and collecting filter, provides a method of analyzing and collecting samples from fluids, such as collecting particulate matter from air. A mass measuring unit and composition analyzing unit can be provided for either simultaneous or immediately consecutive measurements within a single instrument. The filter material can have an antistatic electricity characteristic and can be impregnated with reference material to enable calibration of the composition analyzing unit.
摘要翻译：包括颗粒物分析仪和收集过滤器的系统提供了一种从流体中分析和收集样品的方法，例如从空气中收集颗粒物质。可以提供质量测量单元和组成分析单元用于在单个仪器内的同时或立即连续的测量。过滤材料可以具有抗静电电特性，并且可以用参考材料浸渍以使组合物分析单元能够校准。

9. 发明授权

US08591953B2 Drug carrier and drug carrier kit for inhibiting fibrosis 有权
公开(公告)号：US08591953B2
公开(公告)日：2013-11-26
申请号：US13439330
申请日：2012-04-04
申请人： Yoshiro Niitsu , Junji Kato , Yasushi Sato
发明人： Yoshiro Niitsu , Junji Kato , Yasushi Sato
IPC分类号： A61K9/127 , A61K9/14 , A61K31/07 , C12N15/11 , A61K38/18
摘要： An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.

10. 发明授权

US08178124B2 Drug carrier and drug carrier kit for inhibiting fibrosis 有权
公开(公告)号：US08178124B2
公开(公告)日：2012-05-15
申请号：US13249072
申请日：2011-09-29
申请人： Yoshiro Niitsu , Junji Kato , Yasushi Sato
发明人： Yoshiro Niitsu , Junji Kato , Yasushi Sato
IPC分类号： A61K9/127 , A61K9/14 , A61K31/07 , C12N15/11
CPC分类号： A61K31/07 , A61K9/0019 , A61K9/127 , A61K9/14 , A61K31/7088 , A61K38/1833 , A61K38/1841 , A61K38/1858 , A61K45/06 , A61K47/6911 , Y10S514/893 , Y10T428/2982 , A61K2300/00
摘要： An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式